India is already inside the global healthcare AI regulatory network that Poland committed to join on 22 October 2026, which makes the story relevant for Indian digital health companies, hospitals and regulators. The HealthAI-led network lets member regulators see reviewed AI healthcare tools and share real-time warnings about harmful incidents, and Poland would become its second EU member after Portugal.
Key takeaways: India and the global healthcare AI regulatory network
- India is already a member of the HealthAI Global Regulatory Network, according to a wire-service report.
- Poland would be the second EU member after Portugal; the agreement creates a one-year cooperation framework with no fixed accession date.
- Members get access to AI healthcare tools reviewed by regulators and a real-time warning system for harmful incidents.
- The network supports cooperation; it does not itself approve individual AI products.
- Acumen Research and Consulting estimates the global AI in healthcare market at USD 41.84 billion in 2025.
What India gets from the global healthcare AI regulatory network
The sources we reviewed do not detail India’s own use of the network, so we describe the general benefits the report attributes to members. A regulator can look at AI tools that others have reviewed, and it can use the warning system to report or receive information about harmful incidents. For India, where AI tools are being tested in hospitals, telemedicine and diagnostics, that could mean earlier awareness of problems seen elsewhere. India’s medical device regulator is the Central Drugs Standard Control Organisation, whose site is cdsco.gov.in. We do not say how CDSCO uses the network, because the sources do not.
The market behind the global healthcare AI regulatory network
Acumen Research and Consulting’s report AI in Healthcare Market Size, Share, Forecast Report 2026 to 2035 values the global AI in healthcare market at USD 41.84 billion in 2025 and projects USD 1,136.90 billion by 2035, a compound annual growth rate of 39.1% over 2026 to 2035. It says North America held about 43% of the market in 2025 with a forecast CAGR of 37.8%, Europe held about 25%, and Asia Pacific is projected to grow fastest at 42.5%.
India sits in the Asia Pacific region that Acumen expects to expand fastest, although the report’s regional figures are not specific to India, so we do not attribute them to the country. The figures are Acumen’s estimates and are not statements by HealthAI or by regulators. By our own arithmetic, growth from USD 41.84 billion to USD 1,136.90 billion is a multiple of roughly 27 over ten years, which shows how much the market is expected to expand.
Poland’s move and what it signals for the global healthcare AI regulatory network
The report says Poland agreed on 22 October 2026 to join, and that the agreement sets up a one-year cooperation framework. A HealthAI spokesperson said there is no fixed timeline for Poland’s potential accession. Poland would be the second EU member after Portugal. The report links the move to new EU AI rules and to concern about unpredictable AI behaviour, as set out on the European Commission website.
Current members include Britain, India, Brazil, Singapore, the Philippines, Indonesia, Vietnam, Zambia and Peru, according to the report. The network’s own pages are at healthai.network.
Joining the global healthcare AI regulatory network versus approving an AI product
- A governance network helps regulators share assessments and warnings.
- Product approval or clearance is still decided by each country’s regulator under its own law.
- A tool reviewed by one member does not automatically gain approval in another.
This distinction is our reading of how regulatory networks generally work, and the sources we reviewed do not state it in these terms. It is important for companies, because membership in the network by a country is not a marketing shortcut for an AI product.
Questions Indian health technology companies may ask about the global healthcare AI regulatory network
- Will tools reviewed by other members be easier to assess in India?
- Will incident warnings from abroad lead to checks on products sold in India?
- Will evidence expectations for AI tools become more uniform across members?
- Will the network publish its review criteria?
These are our questions, not answers from the sources. None of them is addressed in the material we reviewed, and we do not speculate on the answers.
General background: why cross-border AI safety matters to the global healthcare AI regulatory network
The same AI tool can be sold in many countries, so a fault found in one place can matter in others. Shared warnings can shorten the time before regulators act. They depend on members reporting honestly and on clear rules about what counts as harm. See also our Healthcare IT section.
Our analysis: what Indian stakeholders should watch
In our assessment, the global healthcare AI regulatory network gives India a seat in an emerging international conversation about health AI safety, but the practical benefits will depend on how actively regulators use it. Companies developing AI tools in India should expect questions about evidence, monitoring and incident reporting to become more consistent across markets.
We cannot say whether Indian regulators will change their own rules because of the network, and the sources do not suggest that they will.
What is not disclosed about the global healthcare AI regulatory network
- India’s date of joining and the services it uses.
- The text of the Poland agreement.
- The number of AI tools reviewed so far.
- How incident reports are verified.
Risks and caveats of the global healthcare AI regulatory network
This article relies on a wire-service report and on third-party market estimates. Membership lists can change. This is news reporting and not legal, regulatory or investment advice.
What to watch next after the global healthcare AI regulatory network deal
- Poland’s formal accession date.
- Any statement from Indian regulators on use of the network.
- Further EU members.
- Publication of shared incident data.
FAQ
Is India in the global healthcare AI regulatory network?
Yes, according to the wire-service report.
What is the market size for AI in healthcare?
Acumen Research and Consulting estimates USD 41.84 billion in 2025, rising to USD 1,136.90 billion by 2035.
Does membership approve AI products?
No. The network supports cooperation between regulators; product approval remains national.
How we reported this: we relied on a wire-service report, the network’s public information and the Acumen Research and Consulting report cited above, and attributed every figure. Last updated 23 October 2026. This is news reporting and not advice.
